Assessing products to counter side effects of GLP-1, says Bayer's Triana

Benchmarks Nifty22,622.70-99.25FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.71 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return19.29 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Assessing products to counter side effects of GLP-1, says Bayer's TrianaBy Rica Bhattacharyya & Vikas Dandekar, ET BureauLast Updated: Oct 12, 2026, 01:33:00 AM ISTSynopsis

Bayer AG plans to expand its consumer health business in India significantly by 2030. The company aims to triple its revenue in the Indian market during this period. Bayer is specifically targeting opportunities in digestive health, nutrition, and multivitamins related to GLP-1 drug side effects. Additionally, Bayer will develop products locally and seek manufacturing partnerships to enhance their market presence.

Listen to this article in summarized format

Loading...×Bayer AG is assessing opportunities to bring products addressing side effects associated with glucagon-like peptide-1 (GLP-1) obesity drugs to India, as the nearly €46 billion German crop and life sciences company seeks to expand its presence in the country. The company is exploring opportunities across digestive health, nutrition, multivitamins and protein supplements to address side effects such as constipation, nausea and muscle loss among patients on GLP-1 therapies, Julio Triana, president of Bayer's Consumer Health Division, told ET's Rica Bhattacharyya & Vikas Dandekar. Bayer aims to triple its consumer health business in India by 2030, anticipating that the country will become its third-largest consumer health market globally. Edited excerpts:

How important is India to Bayer's consumer health business, and what is your growth ambition?

We should be able to triple the India business in terms of the revenue between now and 2030. We have five markets that are a priority for us in consumer health, including the US, which is the largest market in the world for consumer health, China, Germany, and then India and Brazil. In this pecking order, I hope India will get to third. We also would need to be able to bring in more colleagues to be able to drive that business.

Also read: From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

Which product categories offer the biggest growth opportunities in India?

Live Events

There's a huge opportunity in derma. It accounts for about 25% of our business worldwide. In India, it's very small, but the category is huge and it's growing faster than the pain category (in which the company sells Saridon). But we need to continue to innovate based on what the Indian consumer wants. Same thing with Supradyn. Another important area is digestive health, especially in markets like India (which face significant challenges with gut health).

We also have a lot of new entrants in our space. We're competing not just not just with global players like us but also with local players, whose competition can sometimes be even fiercer. Local players may have better proximity to the consumer. We are now running Bayer with a new operating system, which has empowered the local teams to identify market and consumer signals and respond as quickly as they can.

GLP-1 drugs are transforming obesity treatment. What opportunities do you see in products addressing their side effects?

The GLP-1s have brought in a seismic sort of innovation into the market. It is something that benefits too many people. But, as with any such medications, they do have a lot of side effects that other products can help address. In the US, we have a product called MiraLAX for constipation. One of the side effects of GLP-1s is constipation-nausea and sarcopenia are some other effects. And there we have a full range of products in terms of nutrition, multivitamins and single supplements.

Will Bayer bring these products to India?

Yes. The team is doing an assessment. We will support the team to bring whatever products they want to bring to India after scanning the market. We also have a very good network of contract manufacturing here. From the idea to be able to have something in the market in India, it should be very quick.

Will Bayer consider acquisitions or partnerships to expand in India?

We would run the business ourselves, so we're building our own distribution - and so we would not look for a distributing partner... the more products we bring in, we would look for partnerships in manufacturing... And we would look out for inorganic growth opportunities.

Also read: PepsiCo's fizz fades as GLP-1 drugs and activist investor Elliott's targets test its snack business

How will you compete with Indian companies that often have a pricing advantage?

We have a strategy that we call "road to billions". As part of that, in consumer health, our aspiration is that we bring as many of these solutions to as many people as possible. We don't want our products to only be for rich countries that can buy expensive vitamins, etc. It's a strategy that makes sure that our products are reaching as many households as possible. That needs you to be close to what the consumer needs, from pricing and presentations, and cater for that.

How do you view India's regulatory environment for over-the-counter medicines?

I believe that it is currently not an impediment to our plans. We believeself-care is really important, but it must come with a significant level of responsibility. We actually sometimes do see that this is an opportunity in some other markets. The regulation is not like we have in India and then you have people selling anything they want. I sometimes call it "snake oil". At the end of the day, the number one priority is the safety of people taking the products.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onBayer AGConsumer health market in IndiaIndia healthcare marketDigestive health productsconsumer health growth strategiesmultivitamins

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onBayer AGConsumer health market in IndiaIndia healthcare marketDigestive health productsconsumer health growth strategiesmultivitamins

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Login using your ET Prime credentials to enjoy all member benefits

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Big Price Drop! Flat 40% Off

Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail OfferAvail OfferClaim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '

' + h3 + '

' + h4 + '

' + listing + '

'; $('#paidSCWidget').html(html); var callback = $('#paidSCWidget').attr('data-callback'); if(callback && window[callback]) { window[callback](); } customDimension.dimension72 += ' | Shown SYFT no Trial_With Missed Paywalled Articles Collection'; } else { _processNormal() } } }); } else { _processNormal(); } } catch (e) { _processNormal(); } }, function () { _processNormal(); }); //console.log('storyCollectionLoad', $); }

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with
in-depth insights that matter

• Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

  What Adani’s US indictment means for India Inc’s overseas fundraising

• Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

  Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?

• Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

  The problem with lab grown diamonds

• Why a falling rupee is a better option for the economy

  A list of top 20 momentum stocks that have delivered massive returns in one year

2Invest Wisely With Smart Market Tools & Investment Ideas

Alpha Trade

Get daily trade ideas from SEBI-registered research analysts.

Investment Ideas

Grow your wealth with stock ideas & sectoral trends.

Stock Reports Plus

All-in-one stock research with Stock Score, peer comparison & key signals.

BigBull Portfolio

Get to know where the market bulls are investing to identify the right stocks.

Stock Analyzer

Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.

Market Mood

Analyze the market sentiments & identify the trend reversal for strategic decisions.

Stock Talk Live at 9 AM Daily

Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.

3Stay informed anytime, anywhere with ET ePaper

ePaper - Print View

Read the PDF version of ET newspaper. Download & access it offline anytime.

ePaper - Digital View

Read your daily newspaper in Digital View & get it delivered to your inbox everyday.

Wealth Edition

Manage your money efficiently with this weekly money management guide.

TOI ePaper

Read the PDF version of TOI newspaper. Download & access it offline anytime.

Deep Explainers

Explore the In-depth explanation of complex topics for everyday life decisions.

Health+ Stories

Get fitter with daily health insights committed to your well-being.

Personal Finance+ Stories

Manage your wealth better with in-depth insights & updates on finance.

5Enjoy Complimentary Subscriptions From Top Brands

Stream new documentaries from all across the world every day.

Stories you might be interested in